Moderna highlighted its expanding mRNA platform at Science Day, showcasing progress in oncology, autoimmune, rare disease, and next‑generation therapies, while integrating AI and automation to accelerate discovery.
Written By: Chikkula Pavan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
Moderna showcased the expanding capabilities of its messenger RNA (mRNA) platform during its Science Day event, highlighting research and early development programs that support its strategy to diversify beyond infectious disease vaccines into oncology, autoimmune disorders, rare diseases, and next-generation therapeutic modalities.
Chief Executive Officer Stéphane Bancel said the company is preparing to manage three commercial franchises, Infectious Disease Vaccines, Intismeran, and Rare Disease Therapeutics, while advancing a broad research pipeline. He also emphasized the growing role of artificial intelligence (AI), machine learning, automation, and robotics in accelerating discovery and improving research productivity.
Platform strategy drives pipeline expansion
Moderna said its platform integrates mRNA science, delivery science, and manufacturing to support multiple therapeutic modalities. The company uses sentinel programs to generate proof-of-concept data that can de-risk broader platform development.
Its Horizon 1 portfolio includes the approved products Spikevax®, mRESVIA®, mNEXSPIKE®, and mCOMBRAIX®, along with late-stage programs including investigational intismeran autogene therapy and a therapeutic candidate for propionic acidemia. Horizon 2 comprises clinical-stage emerging modalities, while Horizon 3 includes future programs expected to advance into first-in-human studies by the end of 2027.
Oncology pipeline advances
Moderna reported continued progress across several oncology candidates. The Phase 1 study of mRNA-4106 is ongoing in advanced solid tumors, while mRNA-4200 is planned to enter Phase 1 in combination with pembrolizumab.
The company also plans to initiate a Phase 1/2 study this summer evaluating mRNA-4194 in individuals with Lynch syndrome. The investigational candidate represents Moderna’s first cancer prevention program and is designed to prevent progression of pre-malignant lesions to cancer.
Another oncology candidate, mRNA-4359, continues in a Phase 1/2 trial with Phase 2 cohorts enrolling patients with first-line metastatic melanoma and first-line metastatic non-small cell lung cancer.
T-cell engagers and autoimmune programs progress
Moderna’s multiplexed T-cell engager program, mRNA-2808, remains in a Phase 1/2 study for multiple myeloma and incorporates three T-cell engagers targeting clinically validated proteins. Encouraging early clinical findings have also supported advancement of mRNA-2151 into early development for ovarian cancer.
The company also reported progress with mRNA-1195, an investigational therapy targeting Epstein-Barr virus-associated multiple sclerosis. Phase 1 Part B data are expected in the second half of 2026, while the ongoing Phase 2 study has completed enrollment of its sentinel cohort, with the independent Data Safety Monitoring Board recommending dose escalation.
In vivo CAR-T enters future pipeline
Among Horizon 3 programs, Moderna highlighted mRNA-6007, an investigational in vivo CAR-T therapy designed to achieve deep B-cell depletion using targeted lipid nanoparticles and a multiplexed mRNA approach. The initial focus is systemic lupus erythematosus and other B-cell-mediated autoimmune diseases, with the program expected to advance toward first-in-human clinical studies by the end of 2027.
AI powers platform development
Moderna also outlined its Scientific Intelligence Engine, which integrates proprietary and public datasets with AI, machine learning, automation, and robotics to accelerate discovery and create a continuous learning loop that supports future platform development.
Path Forward
Science Day highlighted Moderna’s continued evolution from a vaccine-focused company into a broader mRNA therapeutics developer. Alongside its commercial infectious disease portfolio, the company is expanding its pipeline across cancer immunotherapy, autoimmune diseases, rare genetic disorders, T-cell engagers, and in vivo CAR-T therapies, positioning its mRNA platform for growth across multiple therapeutic areas.
Reference
Moderna Science Day Highlights Expanding Potential of mRNA Platform
About the Writer
Chikkula Pavan Kumar (LinkedIn), PharmD is a Doctor of Pharmacy with a keen interest in clinical pharmacy, pharmacovigilance, and evidence-based practice. In his words, he is passionate about patient safety and translating complex medical information into clear, research-driven communication.